Comparative Pharmacology
Head-to-head clinical analysis: BIAXIN versus E E S 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIAXIN versus E E S 200.
BIAXIN vs E.E.S. 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
None Documented
None Documented
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic